An argument for routine therapeutic drug monitoring of HIV-1 protease inhibitors during pregnancy

AIDS

Volumn 15, Issue 3, 2001, Pages 417-419

  Angel, Jonathan B ^a   Khaliq, Yasmin ^a   Monpetit, Michael L ^b   Cameron, D William ^a   Gallicano, Keith ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

^b HEALTH CANADA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

INDINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; CASE REPORT; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MONITORING; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PREGNANCY; PRIORITY JOURNAL;

ADULT; ANTI-HIV AGENTS; DRUG MONITORING; FEMALE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; NELFINAVIR; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RNA, VIRAL; VIRAL LOAD;

EID: 0035895607     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200102160-00017     Document Type: Article

References (5)

1. Low plasma concentrations of indinavir are related to virologic treatment failure in HIV-1 infected patients on indinavir-containing triple therapy
2. Single and multiple dose pharmacokinetics of nelfinavir and CYP2C19 activity in human immunodeficiency virus-infected patients with chronic liver disease
3. Pharmacokinetic changes during pregnancy and their clinical relevance
4. Pharmacokinetics in pregnancy and placental drug transfer
5. Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus